Should Investors Buy UltraGreen.ai After New US Competition? The Real Test Is Pricing Power
UltraGreen.ai’s Biggest Risk Is Not Losing Market Share — It Is Losing Pricing Power For several years, UltraGreen.ai has enjoyed something investors rarely get in healthcare: a specialised product with high margins, a dominant US market position and relatively little direct competition. That combination is now being tested. Zydus Lifesciences has received US FDA approval